Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” ...

Vertex Pharmaceuticals (NDAQ: VRTX) stands today as a top 20 pharma company with over a $100 billion market cap. But this biotech beacon has ridden a bumpy path to its current perch and, along the way ...

Third, this stock provides stability to investors' portfolios in the event the economy takes a turn for the worse in the new ...

Vertex’s attempt to treat a rare genetic disease has hit another setback. The biotech tossed two more drug candidates onto the discard pile in response to underwhelming data but, following a playbook ...

There are several textbook arguments against monopolies. According to one of them, companies that control a market can lower the quality of their products with impunity. However, Vertex ...

Vertex (NASDAQ:VRTX) is a $76bn market cap, commercial stage pharmaceutical company based in the biotech heartland of Boston, Massachusetts. The company's success in growing revenues from $580m in ...

Vertex Inc. (NASDAQ:VERX) is one of the best beaten down stocks to invest in according to analysts. On December 5, Vertex Inc ...

After a brutal drawdown, Vertex is quietly doing the things long-term investors usually say they want and one fund just ...

Vertex has begun a full-court press for Journavx, enlisting NBA All-Star Jayson Tatum to discuss his use of the new non-opioid painkiller while recovering from a serious injury. Tatum ruptured his ...